Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials
D Huang, L Ke, H Cui, S Li, F Sun - BMC Women's Health, 2024 - Springer
Background Almost all patients with ovarian cancer will experience relapse and eventually
develop platinum-resistant. The poor prognosis and limited treatment options have …
develop platinum-resistant. The poor prognosis and limited treatment options have …
Epothilones as natural compounds for novel anticancer drugs development
C Villegas, I González-Chavarría, V Burgos… - International Journal of …, 2023 - mdpi.com
Epothilone is a natural 16-membered macrolide cytotoxic compound produced by the
metabolism of the cellulose-degrading myxobacterium Sorangium cellulosum. This review …
metabolism of the cellulose-degrading myxobacterium Sorangium cellulosum. This review …
Randomized phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer …
Background Ixabepilone may retain activity in paclitaxel-resistant disease. We previously
reported improved response rates (ORR), progression-free (PFS), and overall survival (OS) …
reported improved response rates (ORR), progression-free (PFS), and overall survival (OS) …
Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized …
Y Xie, F Zhou - Frontiers in Pharmacology, 2024 - frontiersin.org
Background As the development of novel anti-angiogenic drugs and the continuous
evolution of guideline recommendations, the efficacy and safety of anti-angiogenic agents in …
evolution of guideline recommendations, the efficacy and safety of anti-angiogenic agents in …
Efficacy and safety of anti-angiogenic drugs combined with chemotherapy in the treatment of platinum-sensitive/resistant ovarian cancer: a meta-analysis with trial …
H He, F Zhou - Frontiers in Pharmacology, 2024 - frontiersin.org
Background With the emergence of new anti-angiogenic treatments and the ongoing
updates to clinical guidelines, the effectiveness and safety of these agents in treating …
updates to clinical guidelines, the effectiveness and safety of these agents in treating …
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
K Gaitskell, E Rogozińska, S Platt… - Cochrane Database …, 2023 - cochranelibrary.com
Background Many women, and other females, with epithelial ovarian cancer (EOC) develop
resistance to conventional chemotherapy drugs. Drugs that inhibit angiogenesis …
resistance to conventional chemotherapy drugs. Drugs that inhibit angiogenesis …
[HTML][HTML] 埃博霉素类抗肿瘤药物在乳腺癌中的研究进展
孟雪， 胡亚妮， 周海嫔， 刘娟娟 - Hans Journal of Medicinal Chemistry, 2024 - hanspub.org
据2020 年的数据, 全球乳腺癌确诊患者数量增加超过200 万例, 其患病人数超过肺癌成为全球最
常见的癌症类型. 乳腺癌仍然是女性健康的第一杀手. 尽管近年来靶向治疗和免疫治疗取得了 …
常见的癌症类型. 乳腺癌仍然是女性健康的第一杀手. 尽管近年来靶向治疗和免疫治疗取得了 …
Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy
M Danziger, H Noble, DM Roque, F Xu, GG Rao… - Cell and Molecular …, 2024 - Springer
Microtubules are dynamic polymers composed of α-and β-tubulin heterodimers.
Microtubules are universally conserved among eukaryotes and participate in nearly every …
Microtubules are universally conserved among eukaryotes and participate in nearly every …
Bevacizumab and Conventional Chemotherapy for the Treatment of Epithelial Ovarian Cancer: A Systematic Review of the Literature, Best Evidence Synthesis and …
C Silotch - 2023 - search.proquest.com
Background: Ovarian Cancer (OC) is the eighth most commonly diagnosed cancer among
Canadian women, reporting the highest mortality rates among these to date. The lack of …
Canadian women, reporting the highest mortality rates among these to date. The lack of …